Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23093768 | 0.91 | CNR2 (0.56) | CNR2CNR1 | |
| SCHEMBL11972227 | 0.84 | CNR2 (0.74) | CNR2CNR1 | |
| SCHEMBL11971699 | 0.84 | CNR2 (0.74) | CNR2CNR1 | |
| SCHEMBL29718570 | 0.84 | CNR2 (0.74) | CNR2CNR1 | |
| SCHEMBL11972131 | 0.84 | CNR2 (0.74) | CNR2CNR1 | |
| SCHEMBL1516223 | 0.84 | CNR1 (0.60) | CNR2CNR1 | |
| SCHEMBL29836139 | 0.84 | CNR2 (0.72) | CNR2CNR1 | |
| SCHEMBL11971887 | 0.84 | CNR2 (0.72) | CNR2CNR1 | |
| SCHEMBL11971976 | 0.84 | CNR2 (0.72) | CNR2CNR1 | |
| SCHEMBL11971823 | 0.83 | CNR2 (0.72) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12109219-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-11771695-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220306586-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2022-09-29 | — | — | US | disclosed |
| EP-3385252-B1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | disclosed |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| EP-4036089-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-4036082-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| US-11214548-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20170304327-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | disclosed |
| US-20170143704-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-9597340-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9492447-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160271127-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20150126477-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2015-05-07 | — | — | US | disclosed |
| US-20140206649-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2014-07-24 | — | — | US | disclosed |
| US-8778950-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | disclosed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | CNR2 2/4885CNR1 1/4885 |
| US-20140206649-A1 | CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885 |
| US-20160271127-A1 | CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885 |
| US-20170143704-A1 | CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885 |
| US-20150126477-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885 |
| US-20220306586-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | CNR2 2/4885CNR1 1/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | CNR2 2/4885CNR1 1/4885 |
| US-11214548-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | CNR2 2/4885CNR1 1/4885 |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885 |
| US-20170304327-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885 |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | CNR2 2/4885CNR1 1/4885 |
| US-11771695-B2 | Cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885 |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | CNR2 2/4885CNR1 1/4885 |
| US-12109219-B2 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.